univers coverag
calendar event
medic meet chines societi clinic oncolog zlab european respiratori
pleas refer disclosur appendix analyst certif import disclosur price chart
disclosur specif cover compani avail
contact leerink partner editori depart statement valuat risk avail note
follow public contact leerink partner editori depart rx trend deriv im
increment posit commentari gx/biosimilar bu tour
bottom line remain increment posit state gener industri follow
investor meet manag team amneal op telig
takeaway manag includ fda place ad emphasi review approv
complex gener start see first-to-market approv also approv
gener entrant complex gener opportun like character
slower-than-typ launch ramp also extend durat meaning financi contribut due
less overal competitor vs oral-solid gener compani still regard biosimilar asset
attract low penetr biosimilar remicad us op slow start fulphila
extend litig timelin mean manag team look particip space take
prudent approach minim up-front invest
takeaway amneal guidanc
addit readthrough meet coverag univers
sadal kol address controversi ahead registr dlbcl
bottom line ahead top-lin selinexor sadal data diffus larg b-cell lymphoma dlbcl
expect conduct deeper dive dlbcl landscap evalu opportun
selinexor treatment option part dilig spoke two medacorp kol gain
insight evolv dlbcl landscap includ potenti opportun selinexor
dlbcl impact chimer antigen receptor -t cell therapi benchmark upcom
top-lin sadal data dlbcl expect overal view selinexor activ drug could
place dlbcl treatment landscap current estim peak sale selinexor
dlbcl dlbcl opportun contribut pt howev increas
probabl success current base posit top-lin data would increas pt
addit combin opportun earlier line dlbcl repres upsid estim
top-lin sadal data dlbcl continu expect
takeaway kol convers includ
revenu mm
overarch strategi transit revascular
ev/sal multipl sale
bottom line last week host manag meet chairman presid ceo
scott ward senior director ir nielsen what notabl us csii transit strategi
single-product single-geograph compani multi-product multi-national compani deep pipelin
ultim provid complet toolkit revascular overal meet reinforc
view repres sustain double-digit growth stori next year
core busi continu believ compani signific competit advantag
calcifi below-the-kne lesion within peripher drive above-market growth
well grow market-lead posit highli under-penetr coronari market
us long-term guidanc achiev project long-term growth
core pad cad busi leav room upside/offset execut risk new
product launch addit recent manag chang busi develop activ
sale forc restructur posit compani well improv execut acceler
expect slow steadi vyxeo eu
bottom line investor call held earlier today highlight sever nuanc around
vyxeo launch eu european market doubt complex market us
take mani learn us vyxeo launch drive physician awar appropri
patient identif appropri treatment durat eu manag discuss sever factor
contribut complex around eu launch includ variabl standard care treatment
guidelin physician practic reimburs archetyp across countri discuss
detail forecast slow initi ramp product grow
base first order analyt consensu estim assum slightli
faster ramp next year grow
would expect estim get adjust slightli follow today call continu
believ take appropri initi drive vyxeo launch xyrem continu
strong trajectori solriamfetol anoth growth driver jazz strong cash
flow balanc sheet flexibl leverag ratio keep manag good posit pursu
standard care uniform across european countri
agent use similar us differ basi use
guid treatment
variabl across physician treatment practic may leav patient untreat
mani european market regimen standard treatment come consolid
continu see europ attract market ramp field forc launch
european countri differ reimburs archetyp
plan explor vyxeo use broader popul
potenti acquir may back away offer
bottom line cautiou athn follow report elliott may back away
origin offer potenti acquir gone quiet final
bid deadlin extend view elliott initi offer meant mainli initi
sale process consist prior activist campaign without seriou bidder emerg
reduc convict athn sell see greater risk
share return level view delay deadlin final bid may suggest
on-going due dilig led investor recogn account larger slowdown
market detail recent ambulatori survey link
sale
excel news esrx sharehold doj approv first vertic
partial clinic hold lift initi phase data
manag meet highlight potenti reimburs driven upsid
blend dcf price-to-earnings
post-hoc analysi revefenacin ph increment posit
obsv nolasiban oral oxytocin receptor antagonist assist
nolasiban target ivh market larg grow need treatment
implant phase data demonstr direct improv
pregnanc rate day day pregnanc show stat sig improv
pool data
believ data encourag may even suffici approv eu
along posit sub-group analysi ph
look manag provid greater regulatori clariti requir approv
us eu
believ risk-reward skew upsid ahead upcom catalyst
addit look live birth rate data implant posit
go long way improv commerci potenti
believ investor expect head ph data readout
low especi sinc lack clariti around requir approv
still discuss fda around data analysi plan studi link
niemann-pick type np-c ultra-rar progress neurodegen genet
diseas occur bodi properli break cholesterol lipid
lead harm amount lipid accumul spleen liver brain
believ ph i/ii result encourag given breakthrough
statu drug fda prior comment bar approv like low
medacorp specialist spoke enthusiast current
treatment altern off-label use miglustat limit efficaci high ae
rate diarrhea abdomin pain nausea
forecast sale grow larg opportun
believ one sever pipelin asset critic offset
declin key franchis acthar inomax ofirmev face competit
come year posit regulatori execut increas investor
interest emerg pipelin
discuss around approv prospect gener advair posit earn
manag indic complet respons letter june includ minor
label chemistri manufactur control relat question
submit respons mid-juli standard three month goal date
although hope sinc product prioriti design approv could come
manag emphas addit data requir part respons
remain readi launch upon approv
esmo adap present initi efficaci data t-cell receptor tcr
program multipl solid tumor type urotheli melanoma head neck ovarian nsclc
adap clinical-stag biotechnolog compani pioneer develop t-
cell base immunotherapi cancer
compani tcr platform could potenti address solid tumor view
transform cell therapi space success
adap proprietari platform enabl gener engin tcr-base cell therapi
permit target wide rang antigen exploit monoclon
antibodi chimer antigen receptor -t
project probability-weight nsclc scchn bladder sale
expect potenti signific stock price reaction presentaton
initi ph i/ii efficaci data tcr studi non-smal
cell lung cancer nsclc tripl tumor studi
imgn lead proprietari product candid mirvetuximab soravtansin current phase
develop forward-i single-ag platinum-resist ovarian cancer
addit on-going forward-ii phase i/ii studi evalu drug
combin avastin keytruda carboplatin avastin tripl studi advanced/
present data forward-ii avastin combin american societi
clinic oncolog respons rate substanti improv
mirvetuximab monotherapi mark improv progression-fre
surviv durat respons
plan present addit phase ii expans data patient treat
medium high fr-alpha express part keytruda combin
medacorp kol spoken express mix view combin
especi combin keytruda given limit success ovarian cancer
oct dupix asthma indic pdufa
expect dupix sbla approv asthma adult/adolesc patient
consid import catalyst stock
subgroup eosinophil asthma patient dupix confer
exacerb reduct benefit greater lung function benefit approv
-- market drug class eosinophil asthma
believ total product consensu revenu expect surpass
revenu contribut eosinophil asthma patient
given data prefer partner sni focu data label effort
eosinophil patient order highlight superior medicin
full analysi refer note dupi asthma estim dont reflect superior
vs eosinophil asthma outperform
tx award expect announc octob effect date
new contract expect januari
current oper region tx estim market share
submit bid region compani remain posit around retent
least exist tx region
reprocur could mean mm revenu beneficiari
call announc earlier-than-expect complet enrol
follow-up stemi short-term elev myocardi infarct feasibl studi
put data present like aha chicago pivot trial start
possibl earli time-frame sooner base estim
esposito et al publish result anim studi jacc support left
ventricular unload prior reperfus translat human would impli impella
success stemi reduc infarct size prevent late-stag onset
heart failur -- someth would clinic relev also cost effect
concurr editori jacc review clearli bullish implic
esposito studi potenti impella use stemi patient outcom
reproduc human primari mechan lv unload enorm benefit
reduc futur hf event patient acut mi note intervent cardiologist
may also need prepar modifi therapeut strategi mi
estim stemi year would
doubl exist address patient popul high risk pci cardiogen
asln oncology-focus biopharmaceut compani base singapor develop
therapeut global market
compani develop varlitinib indic high preval asia includ
biliari tract cancer gastric cancer
asln expect multipl data readout includ
interim readout phase i/ii studi varlitinib gemcitabin cisplatin line
top-lin data global phase ii/iii studi varlitinib folfox co-
interim data ph ii studi dhodh inhibitor acut myeloid leukemia
believ data present american psychiatr associ confer
provid limit insight genesight endpoint
view test key mygn long-term top-lin growth potenti
drive revenu upsid reimburs mygn desir
current medicar rate
signific controversi alreadi surround reach potenti given
pt trial fail meet primari endpoint met secondari endpoint remiss
respons data may provid sub-
analysi patient fail chang view medacorp specialist payer
journal public expect june coverage/contract decis expect
announc beyond
link takeaway meet manag
regulatori settlement behavior health feder state agenc appear like
posit catalyst
negoti remain on-going manag optimist settlement reach
investig state feder regul year
settlement reserv increas pre-tax
sourc leerink research compani inform factset price prior day
fda adcom neurolog devic panel medic devic
fda adcom vaccin relat biolog product
fda adcom anesthet analges drug product
fda adcom joint gastrointestin drug drug safeti risk
pdufa dupix moder sever asthma adult adolesc
pdufa xyrem cataplexi excess daytim sleepi
pdufa revefenacin lama copd
pdufa bremelanotid hypoact sexual desir disord fda adcom
schedul
chines societi clinic oncolog zlab
data present
zlab brivanib ph ii result
european societi retina specialist euretina nite
american colleg clinic pharmacolog
intern associ studi lung cancer
feder surgeri obes metabol disord
american academi implant dentistri
american societi head neck radiolog
european societi paediatr endocrinolog asnd
european organis research treatmentof cancer iph
american societi bone miner research asnd cmta
american congress rehabilit medicin
american colleg emerg physician
european associ studi diabet
american societi clinic patholog
infecti diseas societi america
foundat prader-willi research zfgn
american colleg gastroenterolog
american colleg chest physician
european colleg neuropsychopharmacolog
congress neurolog surgeon
american societi reproduct medicin
american academi otolaryngolog head neck surgeri aao-hnsf annual
american committe treatment research multipl sclerosi
intern societi technolog arthroplasti
american societi dermatolog surgeri
european associ neuro-oncolog
american associ blood bank
american societi anesthesiologist
european associ nuclear medicin
european societi gene cell therapi
american societi human genet arql
american colleg dentist
european associ cardiothorac surgeri
european societi medic oncolog adap imdz iph
american colleg rheumatolog
go live az
model model recent updat pleas contact leerink
repres wish review
 takeaway immuno-oncolog panel
 takeaway nash panel
biopharma lp hic takeaway ibd panel
 takeaway migrain panel
biopharma lp hic reimburs panel oncolog gene therapi target limit
 rova-t present show anoth rout failur experiment oncolog
adap -- flash manag convers highlight data pipelin progress
adap studi advanc cell dose posit safeti data pt
-- flash present highlight opportun colorect cancer
celg updat strengthen profil remark respons durabl
celg profil continu present outperform
 tazemetostat mesothelioma data opportun combin outperform
 success pamrevlumab lapc may depend endpoint paradigm shift
imdz -- flash event highlight imdz approach strategi outperform
 event highlight investig view forward ii data outperform
-- flash highlight encourag data biomark strategi gastric
-- flash updat demonstr continu safeti earli efficaci
 west coast alzheim kol provid discourag view amyloid aaic
 half full half empti alzheim diseas puls call takeaway market perform
 ctad medacorp call aducanumab abeta hypothesi
biopharma biopharma catalyst tracker import catalyst remain second half
 takeaway annual day
 biotech portfolio concentr explain multipl compress
 first apprais tax offer small benefit
 vertex alexion top pick
-- flash takeaway leerink day outperform
 eas data confirm durabl gocovri superior vs gener
 day preview late stage program turn launch mani
 takeaway annual day
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
 growth deal capac target market
biopharma praluent show mortal benefit lower take aim highest risk group
mdco -- flash inclisiran lesson fourier/odyssey may better
novob dc highlight nvo management roundtabl discuss boston market
 glucagon rescu progress schedul outperform
medic devic ada dash make splash highlight recent
medic devic leerink healthcar confer panel devic penetr set
medic devic leerink leadership seri outset drive shift dialysi self-car
medic devic leerink healthcar confer panel devic penetr set
medic suppli devic initi takeaway sage robot continu gain
medic devic survey support market share re-gain assumpt
medic devices-cardiolog hr takeaway cabana unlik chang af practic
biopharma price right payer fail get drug class come
 stabil sell-sid price trend medic posit ug op outperform
 acthar survey suggest faster eros payer pressur competitor entri
qure updat model higher price assumpt po pt
 price commerci updat fda approv burosumab/crysvita
 respit price yet friendli hill fda could
biopharma trump-azar puls call drug price blueprint limit current hh
 hemophilia price adjust reflect efficaci luxturna paradigm pt
 outlook move higher price clariti suggest possibl upsid pt
hcit distribut blueprint thorough pbm like abl manag rebat
hcit distribut outlin possibl drug price polici draconian
fear
 updat hemophilia price assumpt ad pomp program pt
biopharma futur ibd categori doubl despit
biopharma ibd inflamm market grow
brand ibd medicin grow rais est
celg dose-respons plenti evid activ otezla uc outperform
celg qed ged late stage failur throw ibd bd strategi
celg ozanimod worth rang rrm ibd result outperform
ibd kol call market face disrupt jak displac tnf
uegw highlight fierc competit ibd clear-cut winner
 patent strategi come focu mitig biosimilar risk outpfrm outperform
 news patent decis one remind method use patent
 doubl extend patent horizon tecfidera
 investor sleep path ip protect pt
adap kol address controversi ahead multipl data readout outperform
 anoth setback ido outperform ideal combo still unclear
biopharma what immuno-oncolog takeaway
biopharma summari leerink immuno-oncolog roundtabl
celg anoth bet car-t probabl probabl sensibl even
 deep dive highlight oncolog focu strategi nash market perform
 highlight kol panel lung cancer io cell
celg anoth bet car-t probabl probabl sensibl even
biopharma might deton event look like screen pot match-
 sotp support current stock price where pipelin upsid market
 sotp suggest pipelin free even stock bounc market perform
 dupi miss-inventori demand trend intact partnership flail
biopharma viii partnership acquisit biopharma new top list
ci june ci cfo boston meet insight rais pt outperform
 aet bring comprehens member
dplo mid-mkt pbm acquisit complet strateg move market perform
esrx detail esrx deal term dplo may acquisit target
 evolv provid landscap initi outperform initi
outperform
 partnership valid local jaki gut de-risk develop path pt
 increas pt takeda collabor stock weak offer oppti
manag -- flash gov lose t-twx close without condit posit
pharmaci benefit manag t-twx approv bode pend ci-esrx cvs-
outperform
outperform
perform
outperform
outperform
 research micro-dystrophin
-- contact leerink repres detail access podcast
 pnh survey-soliri still grow like switch monthli sc best
athn survey highlight slow market time take deal pt market
hcit distribut ambulatori survey show slowdown replac market on-going
shift vbc
 vyxeo survey suggest outpati usag grow outperform
 awak w/ solriamfetol rais est follow medacorp survey pt
major medacorp survey lung cancer posit azn
medic devices-cardiolog tavr survey in-lin out-year trend quarter look
ew thv link link
medic suppli devic survey suggest may wait
medic devic survey support market share re-gain assumpt
 acthar survey suggest faster eros payer pressur competitor entri
 bone pick medacorp survey suggest solid crysvita adopt esp
teva rais austedo sale analysi posit medacorp physician survey
 leadership seri growth momentum sustain stemi data catalyst
 open ablat atriclip drive near term growth mi longer term
 leadership seri call highlight upsid potenti neuromodul outperform
 leadership seri busi sourc lt upsid outperform
 differenti poc signific runway impli upsid pt
 leadership seri growth acceler strong gener outperform
 ceo call focus growth outlook potenti upsid area lrp pt
outlook alpha opportun abound healthcar share
